19 September 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today provides an update on its ongoing business development activities.
Business Development Update
AGM Trading Update
12 September 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide a trading update ahead of today’s Annual General Meeting.
Annual Report and Accounts and Notice of AGM
31 July 2018: ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy development company, announces that its Annual Report and Accounts for the year ended 31 March 2018 and the Notice of the 2018 Annual General Meeting (“AGM”) have been sent to shareholders and are also available on the Company’s website at www.reneuron.com.
A copy of the Annual Report can be found by clicking here
Preliminary Results for the year ended 31 March 2018
12 July 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce its preliminary results for the year ended 31 March 2018.
To access the link to the webcast please click here.
Reneuron signs retinal stem cell exclusivity agreement
11 July 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it has signed an exclusivity agreement with a US-based specialty pharmaceutical company in connection with the potential out-licensing of ReNeuron’s hRPC retinal stem cell technology and therapeutic programmes.
Capital Markets Event
04 May 2018:ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is today, as previously announced, hosting a capital markets event focused on the Company’s exosome nanomedicine platform.
Exosome data presented at ISCT conference
04 May 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that new and positive pre-clinical data relating to its ExoPr0 stem cell-derived exosome therapy candidate will be presented today at ISCT 2018, a leading scientific conference taking place this week in Montreal, Canada.
Capital Markets Event and Webcast
30 April 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it will be hosting a capital markets event on the Company’s exosome nanomedicine platform on Thursday 17 May 2018. The event, for analysts and institutional investors, will take place at 2.30pm at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.
ReNeuron wins grant for retinal cell therapy development
19 April 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it is the lead industry participant in a new £1.5 million grant award from the UK’s innovation agency, Innovate UK, to advance development of its hRPC stem cell therapy candidate for blindness-causing degenerative diseases of the retina.
Appointment of US-based Chief Medical Officer
10 April 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that Dr Richard Beckman has joined the Company as Chief Medical Officer. He replaces Dr Julian Howell who has left the Company to pursue another opportunity.